Galvin, Michael
December 2008
Medical Marketing & Media;Dec2008, Vol. 43 Issue 12, p55
Trade Publication
The article presents information on clinical trials related to oncology that were conducted to test the efficacy of drugs including Almorexant Actilion. Aflibercept Regeneron and Lucanix. Two studies examined aflibercept (VEGF Trap) as a single agent in recurrent ovarian and lung cancers. It was found that Regeneron and Sinofi-Aventis afilbercept, also known as VEGF trap is a fully human VEGF receptor fusion protein. A list of other products is also given in the article.


Related Articles

  • PROGEN REPORTS ON PHASE 3 OF PI-88 FOR LIVER CANCER.  // Worldwide Biotech;Feb2008, Vol. 20 Issue 2, p1 

    The article reports that Progen Pharmaceuticals Ltd. has provided an update on clinical trial enrollment associated with its phase 3 hepatocellular carcinoma study. The trial has begun initiating sites and is now open for patient enrollment, through a thorough examination of available surgical...

  • Can ‘phase IV’ work for you? Borfitz, Deborah // Medical Economics;6/6/2003, Vol. 80 Issue 11, p58 

    Focuses on the controversies behind phase IV clinical trials in the U.S. Emphasis on creating a potentiated drug combinations; Collaboration between doctors and pharmaceutical companies to increase drug sales; Quality of drug studies conducted.

  • N.O.'s research facilities prove big draw for clinical drug trials. Kamerick, Megan // New Orleans CityBusiness (1994 to 2008);10/20/2003, Vol. 24 Issue 17, p35 

    Reports on the prevalence of clinical drug trials in New Orleans, Louisiana. Number of trials taking place at the Louisiana State University Health Sciences Center; Impact of the prevalence of clinical trials on the economy of the city; Credibility of academic health science in conducting the...

  • Translational and clinical studies of target-based cancer therapy. Saijo, Nagahiro; Nishio, Kazuto; Tamura, Tomohide // International Journal of Clinical Oncology;Aug2003, Vol. 8 Issue 4, p187 

    The increasing number of negative trials in cancer treatment has prompted a systematic re-evaluation of target-based drugs. It is our impression that the sensitivity of current clinical trial methodology is inadequate to demonstrate the effectiveness of target-based drugs, in terms of tumor...

  • Global clinical trial laboratories decentralize. Rosenberg, Ronald // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p1 

    The article reports that central laboratories which have played an important role in drug development, are now looking for decentralization and regional labs are becoming more active in global clinical trials. With sponsors seeking real-time data access and faster results, labs are conducting...

  • The Quality of Registration of Clinical Trials. Viergever, Roderik F.; Ghersi, Davina // PLoS Clinical Trials;Feb2011, Vol. 8 Issue 2, Special section p1 

    Background: Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some of these problems. However, previous...

  • A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Ruperto, Nicolino; Eichler, Irmgard; Herold, Ralf; Vassal, Gilles; Giaquinto, Carlo; Hjorth, Lars; Valls-i-Soler, Adolf; Peters, Christina; Helms, Peter J.; Raymond, Agnès Saint // Archives of Disease in Childhood;Mar2012, Vol. 97 Issue 3, p185 

    The article discusses several national and international paediatric networks that are performing clinical trials in the paediatric population in Europe. It examines the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), an organization establish to investigate...

  • News in brief . . .  // Reactions Weekly;6/18/2005, Issue 1056, p2 

    Presents updates on issues and events concerning medical researches in the U.S. as of June 2005. Reason for the temporary suspension of the clinical trial for the AV 1101 drug; Recommendations of Bristol-Myers Squibb for pregnant women taking the Sustiva drug; Postponement of the patient...

  • Trial results: the next battle. Abbasi, Kamran // BMJ: British Medical Journal (International Edition);1/15/2005, Vol. 330 Issue 7483, precedes p. 103 p103 

    Presents comments on an announcement by drug companies that results of clinical trials for drugs may soon become available to the public. Concerns about prescription drugs and their possible harmful effects; Assertion that unless the proposal to release clinical trial results is mandatory it...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics